AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2974306 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin (10 mg capsules, 3 capsules/day for 4 weeks, followed by varying doses for 8 weeks)
Number of subjects: 60
Study 2974306 — intervention group
Group type: COMPARATOR
Intervention: Etretinate (10 mg capsules, 3 capsules/day for 4 weeks, followed by varying doses for 8 weeks)
Number of subjects: 60
Study 2974306 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 60
Study 31916391 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound transbronchial lung biopsy with rapid on-site evaluation (EBUS-GS-TBLB + ROSE)
Number of subjects: 138
Study 31916391 — intervention group
Group type: COMPARATOR
Intervention: Endobronchial ultrasound transbronchial lung biopsy without rapid on-site evaluation (EBUS-GS-TBLB without ROSE)
Number of subjects: 138
Study 31362530 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 12156
Study 28941589 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (12 mg intravenous before chemoembolization)
Number of subjects: 88
Study 28941589 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 88
Study 26671340 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Integrated Care (FICare) model
Number of subjects: 675
Study 26671340 — intervention group
Group type: COMPARATOR
Intervention: Standard NICU care
Number of subjects: 675
Study 24097280 — intervention group
Group type: EXPERIMENTAL
Intervention: TRT+TENS
Number of subjects: 30
Study 24097280 — intervention group
Group type: COMPARATOR
Intervention: TRT+PLBO
Number of subjects: 30
Study 22916513 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound technique
Number of subjects: 120
Study 22916513 — intervention group
Group type: COMPARATOR
Intervention: Landmark technique
Number of subjects: 120
Study 20037525 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal suppository (50 mg)
Number of subjects: 80
Study 20037525 — intervention group
Group type: COMPARATOR
Intervention: Tablet (50 mg)
Number of subjects: 80
Study 16390864 — intervention group
Group type: EXPERIMENTAL
Intervention: GH
Number of subjects: 124
Study 16390864 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex steroids
Number of subjects: 124
Study 16390864 — intervention group
Group type: EXPERIMENTAL
Intervention: GH + sex steroids
Number of subjects: 124
Study 16390864 — intervention group
Group type: EXPERIMENTAL
Intervention: GH + testosterone
Number of subjects: 124
Study 16390864 — intervention group
Group type: COMPARATOR
Intervention: HRT
Number of subjects: 124
Study 15214586 — intervention group
Group type: EXPERIMENTAL
Intervention: tibolone 1.25 mg/day
Number of subjects: 162
Study 15214586 — intervention group
Group type: EXPERIMENTAL
Intervention: tibolone 2.5 mg/day
Number of subjects: 162
Study 15214586 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 162
Study 11126502 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine
Number of subjects: 30
Study 11126502 — intervention group
Group type: COMPARATOR
Intervention: 0.5% plain bupivacaine
Number of subjects: 30
Study 9333514 — intervention group
Group type: EXPERIMENTAL
Intervention: Consupren (CS)
Number of subjects: 0
Study 9333514 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (K)
Number of subjects: 0
Study 8475234 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-disclosure condition
Number of subjects: 60
Study 8475234 — intervention group
Group type: COMPARATOR
Intervention: Nondisclosure condition
Number of subjects: 60
Study 3536489 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclizine, 50 mg
Number of subjects: 120
Study 3536489 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine, 2.5 mg
Number of subjects: 120
Study 3536489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 30730798 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) distraction
Number of subjects: 120
Study 30730798 — intervention group
Group type: COMPARATOR
Intervention: Control group (without VR distraction)
Number of subjects: 120
Study 28185407 — intervention group
Group type: COMPARATOR
Intervention: Dialysate temperature at 37°C and sodium concentration at 138 mmol/L (Mode A)
Number of subjects: 4
Study 28185407 — intervention group
Group type: COMPARATOR
Intervention: Dialysate temperature at 35°C and sodium concentration at 138 mmol/L (Mode B)
Number of subjects: 4
Study 28185407 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate temperature at 35°C and sodium concentration changing from 150 mmol/L to 138 mmol/L (Mode C)
Number of subjects: 4
Study 28185407 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate temperature at 35°C and sodium concentration changing from 150 mmol/L to 138 mmol/L (Mode D)
Number of subjects: 4
Study 27422168 — intervention group
Group type: EXPERIMENTAL
Intervention: Yi Jin Jing exercise training
Number of subjects: 150
Study 27422168 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise training
Number of subjects: 150
Study 27422168 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 150
Study 27422168 — intervention group
Group type: EXPERIMENTAL
Intervention: Yi Jin Jing and Tai Chi exercise training
Number of subjects: 150
Study 25049330 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line everolimus followed by sunitinib
Number of subjects: 471
Study 25049330 — intervention group
Group type: COMPARATOR
Intervention: First-line sunitinib followed by everolimus
Number of subjects: 471
Study 25049330 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential everolimus then sunitinib
Number of subjects: 471
Study 25049330 — intervention group
Group type: COMPARATOR
Intervention: Sequential sunitinib then everolimus
Number of subjects: 471
Study 25049330 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line everolimus
Number of subjects: 471
Study 25049330 — intervention group
Group type: COMPARATOR
Intervention: First-line sunitinib
Number of subjects: 471
Study 23014091 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-headed toothbrush
Number of subjects: 4
Study 23014091 — intervention group
Group type: COMPARATOR
Intervention: Single-headed toothbrush
Number of subjects: 4
Study 19651171 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg non-adjuvanted RSV-A vaccine
Number of subjects: 561
Study 19651171 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg adjuvanted RSV-A vaccine
Number of subjects: 561
Study 19651171 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 561
Study 19651171 — intervention group
Group type: COMPARATOR
Intervention: Alum-placebo
Number of subjects: 561
Study 17805456 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal microbicides
Number of subjects: 708
Study 15183941 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatitis patients
Number of subjects: 270
Study 15183941 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 270
Study 12169777 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 20
Study 12169777 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 20
Study 9854507 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous/exogenous TNF therapy (EET) with recombinant TNF‐SAM2 (rTNF‐S) and anti-cancer drugs (mitomycin-C and 5-FU)
Number of subjects: 34
Study 9854507 — intervention group
Group type: COMPARATOR
Intervention: Endogenous/exogenous TNF therapy (EET) alone
Number of subjects: 34
Study 8786726 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg daily)
Number of subjects: 40
Study 8786726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2191749 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of prophylactic antibiotics
Number of subjects: 311
Study 2191749 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of prophylactic antibiotics
Number of subjects: 311
Study 2191749 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion
Number of subjects: 311
Study 2191749 — intervention group
Group type: COMPARATOR
Intervention: No blood transfusion
Number of subjects: 311
Study 517640 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression glove worn during sleep
Number of subjects: 23
Study 517640 — intervention group
Group type: COMPARATOR
Intervention: Loosely fitting glove made of the same material
Number of subjects: 23
Study 31618430 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (25 mg) supplementation
Number of subjects: 4000
Study 31618430 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (2500 IU) supplementation
Number of subjects: 4000
Study 31618430 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron (60 mg) supplementation
Number of subjects: 4000
Study 31618430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4000
Study 31504093 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamin supplementation (200 mg oral thiamin mononitrate per day for 6 months)
Number of subjects: 69
Study 31504093 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 6 months)
Number of subjects: 69
Study 31504093 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamin supplementation
Number of subjects: 69
Study 28407050 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI in women
Number of subjects: 2632
Study 28407050 — intervention group
Group type: COMPARATOR
Intervention: Primary PCI in men
Number of subjects: 2632
Study 28407050 — intervention group
Group type: EXPERIMENTAL
Intervention: Infarct size
Number of subjects: 2632
Study 28407050 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (LVEF)
Number of subjects: 2632
Study 28407050 — intervention group
Group type: EXPERIMENTAL
Intervention: Infarct size as a predictor
Number of subjects: 2632
Study 26096777 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% and benzoyl peroxide 2.5% gel (A-BPO)
Number of subjects: 85
Study 26096777 — intervention group
Group type: COMPARATOR
Intervention: Benzoyl peroxide (BPO)
Number of subjects: 85
Study 26096777 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatological tutorial (DT) for A-BPO application
Number of subjects: 85
Study 26096777 — intervention group
Group type: COMPARATOR
Intervention: Non-tutorial (NT) for A-BPO application
Number of subjects: 85
Study 24732290 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (OFIRMEV [acetaminophen] injection; Cadence Pharmaceuticals, San Diego, CA)
Number of subjects: 30
Study 24732290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21848172 — intervention group
Group type: EXPERIMENTAL
Intervention: CDI 500 in-line blood gas monitor without gas calibration
Number of subjects: 58
Study 21848172 — intervention group
Group type: COMPARATOR
Intervention: CDI 500 in-line blood gas monitor with gas calibration
Number of subjects: 58
Study 21848172 — intervention group
Group type: EXPERIMENTAL
Intervention: CDI 500 in-line blood gas monitor with and without gas calibration after in-vivo calibration
Number of subjects: 58
Study 19068151 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat enriched in walnut paste (WM)
Number of subjects: 22
Study 19068151 — intervention group
Group type: COMPARATOR
Intervention: Low-fat meat (LM)
Number of subjects: 22
Study 19068151 — intervention group
Group type: COMPARATOR
Intervention: Meat enriched in walnut paste (WM) and Low-fat meat (LM)
Number of subjects: 22
Study 17451889 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-methoxytryptamine (5-MTT) at 1 mg/day orally during light phase
Number of subjects: 100
Study 17451889 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (MLT) at 20 mg/day orally during dark phase
Number of subjects: 100
Study 17451889 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 100
Study 17451889 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-methoxytryptamine (5-MTT)
Number of subjects: 100
Study 17451889 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (MLT)
Number of subjects: 100
Study 15088723 — intervention group
Group type: EXPERIMENTAL
Intervention: FM 2/Diafix‐oral
Number of subjects: 80
Study 15088723 — intervention group
Group type: EXPERIMENTAL
Intervention: FM 2/MPS gel
Number of subjects: 80
Study 15088723 — intervention group
Group type: EXPERIMENTAL
Intervention: FM 1/Diafix‐oral
Number of subjects: 80
Study 15088723 — intervention group
Group type: EXPERIMENTAL
Intervention: FM 1/MPS gel
Number of subjects: 80
Study 15088723 — intervention group
Group type: EXPERIMENTAL
Intervention: FM 2/MPS gel (ceramic)
Number of subjects: 80
Study 15088723 — intervention group
Group type: EXPERIMENTAL
Intervention: FM 1/MPS gel (ceramic)
Number of subjects: 80
Study 15088723 — intervention group
Group type: EXPERIMENTAL
Intervention: FM 2/Diamond polisher (ceramic)
Number of subjects: 80
Study 15088723 — intervention group
Group type: EXPERIMENTAL
Intervention: FM 1/Ceramiste silicon polishers (ceramic)
Number of subjects: 80
Study 11509778 — intervention group
Group type: EXPERIMENTAL
Intervention: Microlaparoscopy
Number of subjects: 20
Study 11509778 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopy
Number of subjects: 20
Study 9543160 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep abdominal fat area
Number of subjects: 21
Study 9543160 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous abdominal fat area
Number of subjects: 21
Study 9543160 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body fat
Number of subjects: 21
Study 9543160 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 21
Study 9543160 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist to hip ratio
Number of subjects: 21
Study 9543160 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma triglyceride concentrations
Number of subjects: 21
Study 8304607 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg aerosolized glycopyrrolate
Number of subjects: 125
Study 8304607 — intervention group
Group type: COMPARATOR
Intervention: Aerosolized placebo (control)
Number of subjects: 125
Study 2723098 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration procedure with muco-periosteal flap elevation, granulation tissue removal, root surface debridement, and placement of a teflon membrane.
Number of subjects: 21
Study 2723098 — intervention group
Group type: COMPARATOR
Intervention: Control surgical procedure identical to the test procedure without the placement of membranes.
Number of subjects: 21
Study 31022593 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced Prolonged Exposure (S-PE)
Number of subjects: 335
Study 31022593 — intervention group
Group type: EXPERIMENTAL
Intervention: Massed Prolonged Exposure (M-PE)
Number of subjects: 335
Study 31022593 — intervention group
Group type: EXPERIMENTAL
Intervention: Present Centered Therapy (PCT)
Number of subjects: 335
Study 31022593 — intervention group
Group type: COMPARATOR
Intervention: Minimal Contact Control (MCC)
Number of subjects: 335
Study 29183930 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (0.1%) solution for meatal cleaning prior to catheter insertion
Number of subjects: 0
Study 29183930 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study 25439116 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care with adjunct intervention (guided imagery/relaxation exercises DVD)
Number of subjects: 40
Study 25439116 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study 23224788 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg aprepitant
Number of subjects: 120
Study 23224788 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg aprepitant
Number of subjects: 120
Study 23224788 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 120
Study 21332630 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg
Number of subjects: 4844
Study 21332630 — intervention group
Group type: COMPARATOR
Intervention: Dutasteride 0.5 mg
Number of subjects: 4844
Study 21332630 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (dutasteride 0.5 mg + tamsulosin 0.4 mg)
Number of subjects: 4844
Study 21332630 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 4844
Study 19502544 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide (120 microg)
Number of subjects: 113
Study 19502544 — intervention group
Group type: COMPARATOR
Intervention: Rapid-acting insulin analogs (RAIA)
Number of subjects: 113
Study 19502544 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide
Number of subjects: 113
Study 19502544 — intervention group
Group type: COMPARATOR
Intervention: RAIA
Number of subjects: 113
Study 19502544 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 113
Study 16988169 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib, 40 mg with a 20-mg redose (n = 127)
Number of subjects: 852
Study 16988169 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib, 40 mg with a placebo redose (n = 122)
Number of subjects: 852
Study 16988169 — intervention group
Group type: COMPARATOR
Intervention: Placebo/placebo (n = 125)
Number of subjects: 852
Study 16988169 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib, 20 mg twice daily (n = 160)
Number of subjects: 852
Study 16988169 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib, 20 mg once daily (n = 159)
Number of subjects: 852
Study 16988169 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 159)
Number of subjects: 852
Study 14976881 — intervention group
Group type: EXPERIMENTAL
Intervention: Qinggan Huoxue recipe (QGHXR)
Number of subjects: 120
Study 14976881 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaochaihu granule (XCHG)
Number of subjects: 120
Study 14976881 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 120
Study 11083138 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval test on a cycle ergometer
Number of subjects: 62
Study 11083138 — intervention group
Group type: EXPERIMENTAL
Intervention: Field test with dynamic leg exercises
Number of subjects: 62
Study 11083138 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval wheelchair test on a motor driven treadmill
Number of subjects: 62
Study 11083138 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheelchair field test with dynamic and static arm exercise
Number of subjects: 62
Study 11083138 — intervention group
Group type: EXPERIMENTAL
Intervention: Field test with nursing tasks
Number of subjects: 62
Study 11083138 — intervention group
Group type: EXPERIMENTAL
Intervention: Field test with low and high physiological strain
Number of subjects: 62
Study 9022874 — intervention group
Group type: EXPERIMENTAL
Intervention: Measure of susceptibility to smoking (lack of a firm commitment not to smoke)
Number of subjects: 687
Study 9022874 — intervention group
Group type: EXPERIMENTAL
Intervention: Measure of susceptibility to smoking
Number of subjects: 687
Study 8633187 — intervention group
Group type: EXPERIMENTAL
Intervention: felodipine 5 mg
Number of subjects: 25
Study 8633187 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study 2568838 — intervention group
Group type: EXPERIMENTAL
Intervention: bopindolol (0.05 mg, 0.5 mg, 1 mg, 2 mg)
Number of subjects: 203
Study 2568838 — intervention group
Group type: COMPARATOR
Intervention: nifedipine (2 x 20 mg)
Number of subjects: 203
Study 2568838 — intervention group
Group type: COMPARATOR
Intervention: nifedipine
Number of subjects: 203
Study 2568838 — intervention group
Group type: EXPERIMENTAL
Intervention: bopindolol
Number of subjects: 203
Study 2568838 — intervention group
Group type: EXPERIMENTAL
Intervention: bopindolol and nifedipine
Number of subjects: 203
Study 368770 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (Decadurabolin)
Number of subjects: 27
Study 31378394 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg oral, hourly, with dose escalation)
Number of subjects: 894
Study 31378394 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (200 mg oral, hourly, with dose escalation)
Number of subjects: 894
Study 31378394 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa (1000 mg oral, single dose, no escalation)
Number of subjects: 894
Study 27897406 — intervention group
Group type: EXPERIMENTAL
Intervention: High-level care (HLC)
Number of subjects: 289
Study 27897406 — intervention group
Group type: COMPARATOR
Intervention: Low-level care (LLC)
Number of subjects: 289
Study 27234199 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD treatment participation
Number of subjects: 146
Study 23619700 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Imagery Training (MIT) 30-min, 5 days/week for 4 weeks
Number of subjects: 18
Study 23619700 — intervention group
Group type: COMPARATOR
Intervention: Conventional Rehabilitation Therapy (CRT) 5 days/week for 4 weeks
Number of subjects: 18
Study 23619700 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (MIT and CRT)
Number of subjects: 18
Study 21765808 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot-spot-morning (SSM) scheme
Number of subjects: 6627
Study 21765808 — intervention group
Group type: COMPARATOR
Intervention: Standard spot-morning-spot (SMS) scheme
Number of subjects: 6627
Study 21765808 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot-spot (first two smears of SSM)
Number of subjects: 6627
Study 21765808 — intervention group
Group type: COMPARATOR
Intervention: Spot-morning (first two smears of SMS)
Number of subjects: 6627
Study 21765808 — intervention group
Group type: EXPERIMENTAL
Intervention: SSM scheme
Number of subjects: 6627
Study 21765808 — intervention group
Group type: COMPARATOR
Intervention: SMS scheme
Number of subjects: 6627
Study 19212122 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment for 6 months
Number of subjects: 48
Study 19212122 — intervention group
Group type: COMPARATOR
Intervention: PCOS women
Number of subjects: 48
Study 16648506 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral uracil and tegafur (UFT) plus leucovorin (LV)
Number of subjects: 1608
Study 16648506 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fluorouracil (FU) plus leucovorin (LV)
Number of subjects: 1608
Study 15612616 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of fluconazole 200 mg
Number of subjects: 24